Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

109.64 -4.90 (-4.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,116,250
Open 113.54
Bid (Size) 109.32 (5)
Ask (Size) 109.95 (3)
Prev. Close 114.54
Today's Range 109.45 - 113.81
52wk Range 68.14 - 119.96
Shares Outstanding 1,253,809,440
Dividend Yield 2.88%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GILEAD SCIENCES INC (NASDAQ:GILD) – An Undervalued Biopharmaceutical Stock Worth Considering
GILEAD SCIENCES INC (NASDAQ:GILD) appears undervalued with strong profitability and reasonable financial health, making it a potential candidate for value investors. 
Via Chartmill
Bill Gates Warns Of 'Devestating Effects' Of USAID Funding Cuts: 'It's Not Too Late To Reverse Them'
Bill Gates raises concerns over U.S. aid cuts' impact on HIV programs in Africa and calls for a reversal of the decision. 
Via Benzinga

Performance

YTD
+19.3%
+19.3%
1 Month
+0.3%
+0.3%
3 Month
+5.8%
+5.8%
6 Month
+22.0%
+22.0%
1 Year
+56.7%
+56.7%

More News

Read More
Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know
Via StockStory
Topics ETFs Stocks World Trade
Top S&P500 movers in Friday's session
Via Chartmill
What's going on in today's session: S&P500 movers
Via Chartmill
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Via Benzinga
Topics Government World Trade
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments
Via Stocktwits
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
Via Benzinga
Gilead, Global Fund Enter Agreement To Supply HIV Prevention Drug To Low & Lower-Middle-Income Countries
Via Stocktwits
How Do Investors Really Feel About Gilead Sciences?
Via Benzinga
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'
Via Benzinga
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
From Gilead Sciences, Inc.
Via Business Wire
GILEAD SCIENCES INC (NASDAQ:GILD) - A Strong Technical Setup for Breakout Investors
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Better Dividend ETF to Buy for Passive Income: SCHD or GCOW
Via The Motley Fool
Topics ETFs Stocks
2 Profitable Stocks to Keep an Eye On and 1 to Avoid
Via StockStory
Gilead Sciences: A Mixed Bag of Opportunities and Risks
Via The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
Via Benzinga
Gilead’s Yeztugo HIV Shot Poised For Wider Reach After SCOTUS Ruling On Preventive Coverage: Wells Fargo
Via Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 109.64
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 07/11/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 137.47B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 137B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.